Benefits of early cochlear implantation in children outweigh risks: JAMA

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2020-01-20 08:55 GMT   |   Update On 2020-01-20 08:55 GMT

St Louis, Missouri: A recent study published in the JAMA journal supports the safety of cochlear implants. According to the study results, infectious complications in cochlear implant recipients were low. Also, meningitis was exceedingly rare in such patients. Cochlear implantation is the treatment of choice for patients with severe to profound sensorineural hearing loss. Infections...

Login or Register to read the full article

St Louis, Missouri: A recent study published in the JAMA journal supports the safety of cochlear implants. According to the study results, infectious complications in cochlear implant recipients were low. Also, meningitis was exceedingly rare in such patients. 

Cochlear implantation is the treatment of choice for patients with severe to profound sensorineural hearing loss. Infections resulting from cochlear implantation can result in hearing loss secondary to implant removal and rarely meningitis. 

Infection following cochlear implantation can result in hearing loss secondary to implant removal and, rarely, meningitis. There is a lack of generalizable, large-scale data regarding the risks of infection after implantation. Also, there is a wide variation in rates of infection after cochlear implantation in the published studies. The study by Daniel P. Lander, Washington University School of Medicine in St Louis, St Louis, Missouri, and colleagues aimed to determine the incidence and timing of infectious complications following cochlear implantation.

The researchers conducted the retrospective cohort study using the Healthcare Cost and Utilization Project (HCUP) State Inpatient Databases, State Emergency Department Databases, and State Ambulatory Surgery Databases5 from Florida, Maryland, New York, Vermont, and Wisconsin. Patients aged 1 year and older with an International Classification of Diseases, Ninth Revision or International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-9/10) or Current Procedural Terminology, Fourth Edition procedure code for cochlear implantation in the State Inpatient Databases or State Ambulatory Surgery Databases from January 1, 2006, to September 30, 2016, were included. 

Infectious complications were defined as ICD-9/10 diagnosis codes after implantation for meningitis, petrositis, mastoiditis, prosthetic inflammation/infection, labyrinthitis, postauricular fistula, scalp cellulitis, or site-specific wound complications plus a Staphylococcus or general incision and drainage code. Additionally, ICD-9/10 diagnosis codes within 180 days of implantation for postoperative infection, unspecified cellulitis, or general wound complications plus a Staphylococcus or general incision and drainage code were included as infectious complications. Codes for infectious complications within 2 weeks of each other were considered a single complication. Complications were evaluated separately in children and adults.

Complication rates were calculated per 1000 person-years with 95% confidence intervals, and mean cumulative functions were generated accounting for recurrent infections. Per HCUP standards, events with fewer than 11 cases were not reported to preserve patient anonymity. All statistical analyses were performed in SAS version 9.3 (SAS Institute Inc). This study was exempted from review by the Washington University School of Medicine institutional review board.

Key findings of the study include:

  • In total, 1975 children and 5474 adults received cochlear implants. Of the children, 51% were boys, with a median age at implantation of 4 years (interquartile range [IQR], 2-8 years) and median follow-up of 5.3 years (IQR, 2.5-8.0 years).
  • Infectious complications occurred in 64 children (3.2%) at a rate of 8.2 complications per 1000 person-years.
  • Children aged 1 and 2 years had the highest rates of infectious complications, 15.4 and 14.8 complications per 1000 person-years, respectively.
  • Among the adults, 53% were women, the median age at implantation was 63 years (IQR, 48-75 years), and the median follow-up time was 4.3 years (IQR, 2.0-7.3 years). Infectious complications occurred in 110 adults (2.0%) at a rate of 5.2 complications per 1000 person-years.
  • Adults 65 years and older did not have a higher rate of complications than younger adults.
  • Fifty-five percent (n = 47/86) of pediatric complications occurred within 180 days of implantation, compared with 43% (n = 56/131) of adult complications.
  • Of the 64 children with infectious complications, 22% (n = 14) developed recurrent infectious complications, while 14% (n = 15) of the 110 adults with infectious complications developed recurrent infections.
  • Prosthetic inflammation/infection (n = 86 [40%]) was the most common infectious complication, followed by mastoiditis (n = 56 [26%]) and cellulitis (n = 32 [15%]). Fewer than 11 cases of meningitis were observed.

To sum up the findings -- Young children aged 1 and 2 years experienced infectious complications more frequently than older children. However, the benefits of early implantation on language development are well established and the low absolute risk for infection does not outweigh these substantial benefits.

"The overall increase in infectious complications in children was predominantly driven by repeat and early complications, occurring within 180 days. Increased vigilance by physicians is warranted when caring for young children early after implantation and children with prior implant infections," concluded the authors. 

The study, "Incidence of Infectious Complications Following Cochlear Implantation in Children and Adults," is published in the journal JAMA

DOI: 10.1001/jama.2019.18611

Tags:    
Article Source : JAMA

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News